PEAK6’s Ultragenyx Pharmaceutical RARE Stock Holding History

PEAK6’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,500	Closed	-$358K	–	3509
2024 Q4	$358K	Buy	+8,500	New	+$422K	﹤0.01%	2313

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

PEAK6's RARE Position: Q1 2025 in Review

PEAK6 sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 1,093 shares — an estimated $46K sold.

PEAK6 first reported a position in RARE in Q4 2024 and held it in 1 quarter. The position peaked at $46K in Q4 2024. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

PEAK6 reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
PEAK6 sold 1,093 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $46K.
PEAK6 first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 1 quarter.
PEAK6's Ultragenyx Pharmaceutical position peaked at $46K in Q4 2024.
299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.